Company: SMNR
Filing Date: 2025-03-25
Form Type: PRER14A
Source: 0001013762-25-002297
Chunk: 68

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-25
Form: PRER14A
Chunk 68
---
 to be presented at the extraordinary general meeting, you should contact the Company’s proxy solicitation agent at the following address, telephone number and email: Advantage Proxy, Inc.
P.O. Box 10904
Yakima, WA 98909
Toll -Free: (877) 870 -8565
Collect: (206) 870 -8565
Email: ksmith@advantageproxy.com You may also obtain these documents by requesting them from the Company at: Denali Capital Acquisition Corp.
437 Madison Avenue, 27 thFloor
New York, New York 10022
(646) 978 -5180 If you are a shareholder of the Company and would like to request documents, please do so by [], 2025, in order to receive them before the extraordinary general meeting. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means. 43 Annex A PROPOSED AMENDMENTS TO THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF DENALI CAPITAL ACQUISITION CORP. “RESOLVED, as a special resolution that the Company’s Amended and Restated Memorandum and Articles of Association be amended by deleting Article 49.7 in its entirety and replacing it with the following: 49.7 In the event that the Company does not consummate a Business Combination by April 11, 2025 (the “Termination Date”), or either (i) such earlier date as determined by the Directors or (ii) such later time as the Members may approve in accordance with the Articles, the Company shall: (a) cease all operations except for the purpose of winding up; (b)as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company (less taxes payable and up to US$100,000 of interest to pay dissolution expenses), divided by the number of then Public Shares in issue, which redemption will completely extinguish public Members’ rights as Members (including the right to receive further liquidation distributions, if any); and (c) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Members and the Directors, liquidate and dissolve, subject in each case to